GANX · Gain Therapeutics, Inc.
AI read · Good for GANX
The AI's read
Stable movement scores and a drop in a disease-linked brain substance among patients with higher starting levels give Gain a reason to keep testing rexaceract. The company also reported no new safety concerns. These were early, open-label results from 12 patients, so they do not prove the drug slows Parkinson's disease. A Phase 2 study is still planned, and more study is needed to see whether the drug helps patients.